CurrentCapital BluecrossPolicy MP 4.046

Sphenopalatine ganglion (SPG) block for headache

Defines Capital Bluecross coverage stance for SPG blocks used to treat migraine and non-migraine headaches across applicable products; affects providers submitting claims for this procedure under the payer's covered programs.

Policy Summary

PayerCapital Bluecross

PolicySphenopalatine ganglion (SPG) block for headache

Policy CodePolicy MP 4.046

Change TypeNo material changes

Effective DateAug 1, 2025

Next Review DateN/A

Key ActionVerify member eligibility, benefits, and prior authorization requirements with the specific Capital Bluecross product before submitting claims.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

investigationalcoverage stance

3Procedure codes

3FDA devices named

MultiplePolicy history

Coverage Determination and Rationale

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

General coverage determination

Covered when ALL of the following are met:

Investigational for all headache indications: Sphenopalatine ganglion blocks are considered investigational for all headache indications, including but not limited to the treatment of migraines and non-migraine headaches

Coverage not recommended due to insufficient evidence of improved health outcomes

Sphenopalatine ganglion (SPG) blocks are not covered for any headache indications. Capital Blue Cross considers SPG blocks investigational for all headache types, including but not limited to migraine and non-migraine headaches, because the available evidence is insufficient to support a conclusion that the procedure improves net health outcomes.

The evidence base across multiple headache indications is limited and inconsistent. For chronic migraine, a single randomized trial demonstrated short-term benefit (up to 24 hours) after a regimen of 12 SPG blocks but did not show significant longer-term effects and was underpowered to assess sustained outcomes. For acute severe headache in the emergency setting, one RCT showed greater rates of headache freedom at 24 hours but otherwise no consistent benefit. For postdural puncture headache (PDPH), a systematic review of 9 randomized trials (N=381) found SPG blocks improved pain at some early time points (30 minutes, 1 hour, 4 hours) but not consistently at later intervals; studies varied in anesthetic agents, concentrations, and design. Overall, the literature is insufficient to conclude SPG blocks improve meaningful, durable health outcomes across chronic migraine, acute severe headache, cluster headache, or PDPH.

Identification of procedure codes or inclusion in the coding section does not imply that SPG blocks are a covered benefit. Coverage for any specific service is determined by the member's benefit plan and the terms of member benefit information. Additionally, some services listed may not be eligible for separate reimbursement even if otherwise covered under a member's plan.

Procedure and Billing Codes

Coding information (not specified in provided text)mixed

Not listed in excerpt

Document notes coding information section; specific procedure/diagnosis codes are not present in this excerpt.

Procedure CodesCPT

64400	Injection, anesthetic agent; stellate ganglion (note: code listed in document as procedure code)
64505	Injection, anesthetic agent; sphenopalatine (pterygopalatine) ganglion (note: code listed in document as procedure code)
64999	Unlisted procedure, nervous system (note: code listed in document as procedure code)

Provider Responsibilities and Prior Authorization

Prior Authorization

Product variations and prior authorization

This policy applies only to certain Capital Blue Cross programs and products and may be subject to product-specific benefit variations and prior authorization requirements. Verify whether the member's plan or product requires prior authorization or has specific exclusions or limits before rendering services. For Federal Employee Program (FEP) PPO members, refer to the FEP Medical Policy Manual: https://www.fepblue.org/benefit-plans/medical-policies-and-utilization-management-guidelines/medical-policies

Applies to specific products and programs administered by Capital Blue Cross; product-level benefit variations may alter coverage or prior authorization requirements.
FEP PPO: see FEP Medical Policy Manual (link above).

Billing Rule

Procedure codes listed

The following procedure codes are listed for reference only. Identification of a code here does not guarantee coverage; coverage and reimbursement depend on the member's benefit terms and medical necessity.

Procedure codes listed: 64400, 64505, 64999
Code lists may not be all-inclusive and are subject to change.

Denial Risk

Investigational — denial risk

Sphenopalatine ganglion (SPG) blocks are considered investigational for all headache indications (including migraine and non-migraine headaches). Claims for SPG block procedures for headache indications may be denied on the basis that the service is investigational.

Investigational for all headache indications — denial risk for headache-related claims.

Documentation Required

Coverage verification and member benefit confirmation

Coverage and payment are determined by the terms of the member's benefit program and eligibility on the date of service. Providers must verify member eligibility, benefits, and any medical necessity requirements prior to providing services. These medical policies do not guarantee coverage or payment.

Verify member eligibility and benefit details (including limits, exclusions, prior authorization).
Ensure documentation supports medical necessity per the member's plan.

Clinical Background and Scope

Sphenopalatine ganglion (SPG) blocks involve topical application of local anesthetic to the mucosa overlying the sphenopalatine ganglion, typically via a transnasal approach using an intranasal catheter or applicator to reach the posterior nasal wall and target the ganglion. These procedures have been proposed to provide symptomatic relief for various headache disorders, including chronic migraine, acute severe headaches, cluster headache, and postdural puncture headache, but clinical trial evidence to date has not demonstrated consistent, durable benefits.

Key Definitions

Sphenopalatine ganglion block (topical intranasal application)

TechniqueTopical intranasal application of local anesthetic to the mucosa overlying the sphenopalatine ganglion, typically delivered via an intranasal catheter attached to a syringe

Target anatomySphenopalatine (pterygopalatine) ganglion located on the posterior wall of the nasal cavity, linked to the trigeminal system

Delivery devicesIntranasal catheters (commercially available devices described in policy) used to apply lidocaine or bupivacaine to the posterior nasal wall

Historical techniqueOlder method used cotton-tipped applicators dabbed with local anesthetic but is less accurate than catheter delivery

Chronic migraine — definition

Diagnostic thresholdMigraine attacks on at least 15 days per month for more than 3 months

Migraine features requirementHeadache features of migraine present on at least 8 days per month

Duration criterionCriteria apply for a period exceeding 3 months

Postdural puncture headache (PDPH) — definition and features

Typical onset settingOccurs after lumbar puncture or unintended dural puncture (including during epidural anesthesia)

Characteristic natureBilateral frontal or occipital headache that worsens with sitting or standing and is relieved by lying flat (orthostatic)

Associated symptomsMay include nausea, neck stiffness, low back pain, tinnitus, and visual disturbances

Sphenopalatine ganglion block — general procedure definition

Procedure overviewA procedure intended to provide symptomatic relief for headache disorders by blocking the SPG via transnasal (intranasal catheter) or other approaches

Transnasal approachInsertion of an intranasal catheter to the posterior nasal wall with application of local anesthetic (e.g., lidocaine, bupivacaine) to reach the ganglion

Alternative/adjunct approachesHistorically cotton-tipped applicators have been used; neurostimulation and radiofrequency lesioning of the SPG have been described but are not FDA-cleared in the U.S.

Intended effectBlock sensory fibers of the SPG to reduce pain while maintaining autonomic function